Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Dermatología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Reclutando
Fase 3
ClinicalTrials.gov
Prospective, Randomised, DBPC, Multicenter Clinical Trial to Evaluate Efficacy and Safety of Sublingual Immunotherapy in Patients With Rhinitis/Rhinoconjunctivitis With or Without Mild to Moderate Asthma, Allergic to Dpt and/or Df
INTERVENTIONAL
Inicio: 2 de abr de 2025
ID: NCT07348302
Completado
Fase 1
ClinicalTrials.gov
A Randomized, Double-blind, Parallel Groups, Phase 1 Clinical Study Comparing the Pharmacokinetic, Safety and Immunogenicity of Adalimumab in Healthy Subjects
INTERVENTIONAL
Inicio: 1 de ago de 2022
ID: NCT06291948
Completado
Fase 4
ClinicalTrials.gov
A Single-blind, Randomized, Comparative Pilot Study Evaluating the Tolerability of Two Topical Combination Therapies in the Treatment of Acne Vulgaris
INTERVENTIONAL
Inicio: 1 de feb de 2009
ID: NCT00887484
Completado
ClinicalTrials.gov
A Prospective Non-interventional Study to Collect Real Life Clinical Data on the Impact of Therapy, the Diagnosis and Management of Chronic Urticaria in Patients Refractory to at Least One Course of H1 Antihistamine Therapy
OBSERVATIONAL
Inicio: 24 de dic de 2014
ID: NCT02626221
Completado
ClinicalTrials.gov
Benefit of a Dermocosmetic in Mild to Moderate Adult Acne
OBSERVATIONAL
Inicio: 1 de jul de 2019
ID: NCT05483205
Completado
Fase 2
ClinicalTrials.gov
A Phase II, Multicenter, Randomized, Double Masked, Active Comparator-Controlled Study to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7200220 Administered Intravitreally in Patients With Diabetic Macular Edema
INTERVENTIONAL
Inicio: 31 de dic de 2021
ID: NCT05151731
Completado
Fase 3
ClinicalTrials.gov
A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Ixekizumab Dosing Regimens in Patients With Moderate-to-Severe Plaque Psoriasis
INTERVENTIONAL
Inicio: 1 de ago de 2015
ID: NCT02513550
Completado
Fase 3
ClinicalTrials.gov
The NEMO Trial (NRAS Melanoma and MEK Inhibitor):A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
INTERVENTIONAL
Inicio: 12 de jul de 2013
ID: NCT01763164
Completado
Fase 3
ClinicalTrials.gov
Master Protocol of Three Randomized, Double-blind, Placebo Controlled, Multi-center, Parallel-group Studies of Dupilumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite the Use of H1 Antihistamine Treatment in Patients naïve to Omalizumab and in Patients Who Are Intolerant or Incomplete Responders to Omalizumab
INTERVENTIONAL
Inicio: 11 de dic de 2019
ID: NCT04180488
Aún no recluta
Fase 3
ClinicalTrials.gov
Prospective, Randomised, DBPC Clinical Trial to Evaluate the Efficacy and Safety of Polymerized and Mannan Conjugated Allergen Extract of Dermatophagoides for the Treatment of Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma
INTERVENTIONAL
Inicio: 1 de nov de 2023
ID: NCT05641272
Completado
Fase 2
ClinicalTrials.gov
An Open-label, Multicenter, Extension Study to Evaluate the Long-term Safety and Tolerability of LOU064 in Eligible Subjects With CSU Who Have Participated in CLOU064A2201
INTERVENTIONAL
Inicio: 24 de oct de 2019
ID: NCT04109313
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
INTERVENTIONAL
Inicio: 19 de ago de 2024
ID: NCT06461897
Terminado
Fase 3
ClinicalTrials.gov
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra®) in Adults With Dermatomyositis (DM) - The RECLAIIM Study
INTERVENTIONAL
Inicio: 21 de oct de 2019
ID: NCT04044690
Completado
Fase 3
ClinicalTrials.gov
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
INTERVENTIONAL
Inicio: 28 de mar de 2017
ID: NCT03073200
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Multicenter, Open-Label, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin Versus Active Comparator in Pediatric Subjects With Acute Bacterial Skin and Skin Structure Infections
INTERVENTIONAL
Inicio: 30 de mar de 2017
ID: NCT02814916
Completado
Fase 4
ClinicalTrials.gov
A Randomized, Multicenter STudy to Evaluate the Effect of Secukinumab 300 mg s.c. Administered During 52 Weeks to Patients Suffering From New-onset Moderate to Severe Plaque Psoriasis as Early Intervention Compared to Standard Treatment With Narrow-band UVB (STEPIn Study)
INTERVENTIONAL
Inicio: 27 de mar de 2017
ID: NCT03020199
Completado
Fase 3
ClinicalTrials.gov
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation
INTERVENTIONAL
Inicio: 1 de jun de 2011
ID: NCT01272219
Terminado
Fase 3
ClinicalTrials.gov
A Randomized, Double-blind, Placebo-controlled, Phase III Study Comparing the Combination of PDR001, Dabrafenib and Trametinib Versus Placebo, Dabrafenib and Trametinib in Previously Untreated Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
INTERVENTIONAL
Inicio: 17 de feb de 2017
ID: NCT02967692
Completado
Fase 3
ClinicalTrials.gov
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
INTERVENTIONAL
Inicio: 26 de jun de 2018
ID: NCT03535194
Reclutando
Fase 3
ClinicalTrials.gov
A Randomized, Double-blind, Double-dummy, Placebo-controlled, Multicenter, Phase 3 Study Assessing the Efficacy, Safety, and Tolerability of 2 Doses of Remibrutinib Over a 68-week Treatment Period in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE-2)
INTERVENTIONAL
Inicio: 20 de mar de 2025
ID: NCT06840392
Anterior
1
...
6
7
8
...
434
Siguiente
Filtros